<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04194957</url>
  </required_header>
  <id_info>
    <org_study_id>M19ALP</org_study_id>
    <nct_id>NCT04194957</nct_id>
  </id_info>
  <brief_title>Improving the Safety of Fluoropyrimidine-based Chemotherapy</brief_title>
  <acronym>Alpe2U</acronym>
  <official_title>Improving the Safety of Fluoropyrimidine-based Chemotherapy by Combined DPYD Genotype-guided and DPD Phenotype-guided Dose Individualization: The ALPE2U Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study it will be determined whether the rate of severe toxicity associated with
      fluoropyrimidine treatment (capecitabine or 5-fluorouracil) can be significantly diminished
      by individualized dosing of fluoropyrimidines based on upfront phenotypic assessment of
      dihydropyrimidine dehydrogenase (DPD) deficiency.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study a phenotypic approach will be studied to determine the additional value of
      pretreatment uracil level-guided dose individualization in wildtype patients. Patients with a
      pretreatment serum uracil concentration above 16 ng/ml will be treated with a 50% reduced
      fluoropyrimidine starting dose. The pretreatment serum uracil levels in DPYD variant carriers
      will be assessed retrospectively and non-interventional. Additionally, the effect of a higher
      dose reduction in c.1236G&gt;A and c.2846A&gt;T DPYD variants carriers (50% instead of 25%) will be
      studied.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2020</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: incidence of severe fluoropyrimidine-related toxicity (CTCAE grade 3 to 5) in wild type patients</measure>
    <time_frame>Patients with a pre-treatment uracil concentration above 16 ng/ml will be followed until end of treatment (expected average of 1 year). Otherwise, patients will be followed for the first 2 cycles (each cycle is 28 days).</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: incidence of severe treatment-related toxicity (CTCAE grade 3 to 5) in heterozygous carriers of c.1236G&gt;A or c.2846A&gt;T DPYD variants</measure>
    <time_frame>Patients will be followed during fluoropyrimidine treatment, expected average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacokinetics: Such profile parameters will include Cmax, Tmax, AUC and elimination half-life</measure>
    <time_frame>During the first administration of fluoropyrimidine treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness: medical costs that are made during fluoropyrimidine treatment seen from a health care perspective</measure>
    <time_frame>Patients will be followed during fluoropyrimidine treatment, expected average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of feasibility of dose titration following an initial dose reduction</measure>
    <time_frame>During fluoropyrimidine treatment, expected average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of geriatric parameters for grade 3-5 toxicity and/or treatment discontinuation</measure>
    <time_frame>During fluoropyrimidine treatment, expected average of 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1440</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Wild type for DPYD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients screened for four single nucleotide polymorphisms (SNPs) in DPYD (DPYD*2A, c.2846A&gt;T, c.1236G&gt;A/HapB3 and DPYD*13) that are found to be wild type for these SNPs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>heterozygous carrier of c.1236G&gt;A or c.2846A&gt;T DPYD variant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients screened for four single nucleotide polymorphisms (SNPs) in DPYD (DPYD*2A, c.2846A&gt;T, c.1236G&gt;A/HapB3 and DPYD*13) that are found to be heterozygous for c.1236G&gt;A or c.2846A&gt;T of these SNPs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Homozygous or compound heterozygous carrier of DPYD variants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients screened for four single nucleotide polymorphisms (SNPs) in DPYD (DPYD*2A, c.2846A&gt;T, c.1236G&gt;A/HapB3 and DPYD*13) that are found to be homozygous or compound heterozygous for these SNPs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoropyrimidine (capecitabine or 5-fluorouracil)</intervention_name>
    <description>Patients that are found to be wild type and have a pre-treatment uracil concentration above 16 ng/mL will receive a reduced dosage of capecitabine or 5-fluorouracil (50% reduction). The dose will be titrated after 2 cycles , to achieve maximal safe exposure. Patients that are wildtype with a uracil concentration below 16 ng/mL will receive a normal (full) dose.</description>
    <arm_group_label>Wild type for DPYD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoropyrimidine (capecitabine or 5-fluorouracil)</intervention_name>
    <description>Patients that are heterozygous carriers of c.1236G&gt;A or c.2846A&gt;T DPYD variant will receive a reduced dosage of capecitabine or 5-FU (50 % reduction). The dose will be titrated after 2 cycles, to achieve maximal safe exposure.</description>
    <arm_group_label>heterozygous carrier of c.1236G&gt;A or c.2846A&gt;T DPYD variant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoropyrimidine (capecitabine or 5-fluorouracil)</intervention_name>
    <description>Patients with homozygous or compound heterozygous DPYD variants will be treated with a reduced dose of capecitabine or 5-FU based on the DPD enzyme activity measured in peripheral blood mononuclear cells.</description>
    <arm_group_label>Homozygous or compound heterozygous carrier of DPYD variants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pathologically confirmed malignancy for which treatment with a fluoropyrimidine is
             considered to be in the patient's best interest

          2. Patient need to be of Western descent

          3. Age ≥ 18

          4. Able and willing to give written informed consent

          5. WHO performance status of 0, 1 or 2

          6. Able and willing to undergo extra blood sampling for study related analysis

          7. Adequate baseline patient characteristics, in the opinion of the treating physician
             (complete blood count, hepatic function which involves serum bilirubin, AST, ALT, and
             renal function)

        Exclusion Criteria:

          1. Prior treatment with fluoropyrimidines

          2. Patients with known substance abuse, psychotic disorders, and/or other diseases
             expected to interfere with study or the patient's safety in the opinion of the
             treating physician

          3. Patients treated with the combination of a fluoropyrimidine and irinotecan
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annemieke Cats, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Netherlands Cancer Institute - Antoni van Leeuwenhoek</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jonathan Knikman, PharmD</last_name>
    <phone>+31 (0)20 512 9111</phone>
    <email>j.knikman@nki.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Annemieke Cats, MD, PhD</last_name>
    <email>a.cats@nki.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Netherlands Cancer Institute - Antoni van Leeuwenhoek</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annemieke Cats, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, Creemers GJ, Baars A, Dezentjé VO, Imholz ALT, Jeurissen FJF, Portielje JEA, Jansen RLH, Hamberg P, Ten Tije AJ, Droogendijk HJ, Koopman M, Nieboer P, van de Poel MHW, Mandigers CMPW, Rosing H, Beijnen JH, Werkhoven EV, van Kuilenburg ABP, van Schaik RHN, Mathijssen RHJ, Swen JJ, Gelderblom H, Cats A, Guchelaar HJ, Schellens JHM. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol. 2018 Nov;19(11):1459-1467. doi: 10.1016/S1470-2045(18)30686-7. Epub 2018 Oct 19.</citation>
    <PMID>30348537</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 15, 2019</study_first_submitted>
  <study_first_submitted_qc>December 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2019</study_first_posted>
  <last_update_submitted>January 20, 2020</last_update_submitted>
  <last_update_submitted_qc>January 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fluoropyrimidines</keyword>
  <keyword>Phenotyping</keyword>
  <keyword>Genotyping</keyword>
  <keyword>Dose-individualization</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>5-Fluorouracil</keyword>
  <keyword>5-FU</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

